In the past week, LTRN stock has gone up by 9.66%, with a monthly gain of 12.46% and a quarterly plunge of -8.33%. The volatility ratio for the week is 9.85%, and the volatility levels for the last 30 days are 10.97% for Lantern Pharma Inc The simple moving average for the past 20 days is 1.67% for LTRN’s stock, with a -26.59% simple moving average for the past 200 days.
Is It Worth Investing in Lantern Pharma Inc (NASDAQ: LTRN) Right Now?
The 36-month beta value for LTRN is also noteworthy at 1.55. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LTRN is 8.04M, and at present, short sellers hold a 2.53% of that float. The average trading volume of LTRN on December 27, 2024 was 54.19K shares.
LTRN) stock’s latest price update
Lantern Pharma Inc (NASDAQ: LTRN) has experienced a rise in its stock price by 12.64 compared to its previous closing price of 3.12. However, the company has seen a gain of 9.66% in its stock price over the last five trading days. businesswire.com reported 2024-12-09 that DALLAS–(BUSINESS WIRE)–Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that the first patient has been enrolled and dosed in Taiwan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The enrollment of the first patie.
Analysts’ Opinion of LTRN
Many brokerage firms have already submitted their reports for LTRN stocks, with H.C. Wainwright repeating the rating for LTRN by listing it as a “Buy.” The predicted price for LTRN in the upcoming period, according to H.C. Wainwright is $32 based on the research report published on October 07, 2021 of the previous year 2021.
LTRN Trading at 3.83% from the 50-Day Moving Average
After a stumble in the market that brought LTRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.64% of loss for the given period.
Volatility was left at 10.97%, however, over the last 30 days, the volatility rate increased by 9.85%, as shares surge +14.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.56% lower at present.
During the last 5 trading sessions, LTRN rose by +9.66%, which changed the moving average for the period of 200-days by -54.29% in comparison to the 20-day moving average, which settled at $3.46. In addition, Lantern Pharma Inc saw -17.76% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LTRN starting from Fletcher Aaron G.L., who sale 20,000 shares at the price of $6.33 back on May 24 ’24. After this action, Fletcher Aaron G.L. now owns 57,467 shares of Lantern Pharma Inc, valued at $126,600 using the latest closing price.
Fletcher Aaron G.L., the 10% Owner of Lantern Pharma Inc, sale 10,000 shares at $6.25 during a trade that took place back on May 23 ’24, which means that Fletcher Aaron G.L. is holding 59,326 shares at $62,500 based on the most recent closing price.
Stock Fundamentals for LTRN
Current profitability levels for the company are sitting at:
- -81.2 for the present operating margin
- 0.64 for the gross margin
The net margin for Lantern Pharma Inc stands at -73.13. The total capital return value is set at -0.79. Equity return is now at value -53.03, with -48.91 for asset returns.
Currently, EBITDA for the company is -15.79 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 115.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.31.
Conclusion
In summary, Lantern Pharma Inc (LTRN) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
